Stop-Loss Insurance: International Pricing Below Attachment Points
US commercial hospital prices remain at 254% of Medicare (RAND, 2024). Approximately half of US metropolitan areas are served by one or two health systems for all inpatient commercial care (Peterson-KFF Health System Tracker). Domestic cost containment tools operate within a market that lacks structural conditions for price competition.
International JCI-accredited hospitals operate in the inverse condition: competing for patients across borders on published pricing, without insurer-negotiated rate complexity or payer-specific opacity. The resulting price differentials on the procedures driving stop-loss claims are 40-80%.
The Structural Pricing Problem in US Healthcare
US commercial hospital prices have remained at or above 254% of Medicare since 2018, according to the RAND Corporation's Hospital Price Transparency Study (Round 5.1, May 2024). The Peterson-KFF Health System Tracker documents that approximately half of US metropolitan areas are served by one or two health systems for all inpatient commercial hospital care. This market concentration is the structural explanation for the RAND figure: hospitals operating in concentrated markets face limited competitive pressure on price.
Domestic cost containment mechanisms (narrow networks, reference-based pricing, bundled payment arrangements, direct provider contracting) have produced incremental reductions within this concentrated market but have not altered the structural pricing dynamic. Reference-based pricing generates provider friction. Narrow networks generate employee friction. Bundled payments reduce unit cost variability but do not address the base pricing level. Each tool operates within the same concentrated domestic market.
International JCI-accredited hospitals operate in a structurally different market condition. They compete for patients across national borders on published pricing. There is no insurer-negotiated rate complexity, no payer-specific pricing variation, and no opacity as a competitive strategy. Transparent pricing is the mechanism by which these facilities attract patient volume. This structural difference produces the 40-80% price differentials documented in the following sections.
High-Cost Claim Frequency and Severity, 2020-2025
Million-dollar claims per million covered employees increased 61% between 2020 and 2024, according to Sun Life's 2025 High-Cost Claims Report (based on 65,000+ claims from 3,000 employers). The 2020 base year reflects COVID-related elective procedure deferrals, which depressed claim frequency; the growth rate captures both secular trend and post-pandemic recovery. The proportion of self-funded plans reporting at least one claim exceeding $1 million rose from 23% to 49% in the same period. Voya's 2025 Paid Claims Analysis reports their average top-10 individual claims reached $6.6 million each, with 47 members exceeding $3 million and 10 exceeding $5 million.
Three procedure categories dominate stop-loss reimbursements. Cancer accounts for $1.2 billion across approximately 5,000 claims (Sun Life, 2025), driven primarily by biologics, immunotherapy, and cell and gene therapy rather than elective surgical procedures. Cardiovascular disease occupies the second position. Musculoskeletal conditions entered the top three for the first time in 2024, accounting for $1.18 billion at an average claim cost of $116,000. International pricing differentials are most pronounced in the latter two categories: cardiac, orthopaedic, and bariatric surgery at JCI-accredited facilities publish at 40-80% below US commercial rates. Cancer treatment, which drives the largest aggregate stop-loss category, is largely outside the scope of elective international surgical pricing.
Stop-loss premium trends reflect this severity acceleration. Segal's 2025 National Medical Stop-Loss Premium Survey documents average increases of 9.7%, with longer-term growth reaching 9.9% to 12.1%. Voya implemented increases averaging 21% for 2025 renewals, explicitly citing "advanced cancer treatments, premature births, and health systems increasing revenue for surgical and acute care" as drivers. The US stop-loss market reached $35.4 billion in 2024. One market research projection (Allied Market Research) estimates $113.5 billion by 2034 at 15.1% CAGR, though market research projections for mature insurance lines at this growth rate should be interpreted with caution.
Published Procedure Pricing at JCI-Accredited International Facilities
The following table presents published pricing at JCI or equivalent nationally accredited international facilities alongside US commercial pricing for the same procedure categories. International prices represent standard rates at facilities operating profitably. These are not negotiated discounts or promotional arrangements. International hospitals publish pricing willingly as a competitive mechanism; no mandate equivalent to US Transparency in Coverage rules was required to produce this data.
| Procedure | US Commercial Price | International Price Examples | US Source | Int'l Source |
|---|---|---|---|---|
| Coronary Artery Bypass (CABG) | $70,000 - $150,000 | India $7,900 | Turkey $13,900 | Colombia $11,200 | iFHP 2024, JAHA 2024 | iFHP 2024 |
| Hip Replacement (Total) | $40,000 - $177,000 | India $7,200 | Mexico $14,000 | Colombia $12,000 | Trilliant 2025, World Population Review 2025 | iFHP 2024, World Population Review 2025 |
| Knee Replacement (Total) | $30,000 - $75,000 | India $6,600 | Turkey $10,400 | Mexico $12,000 | Trilliant 2025, KFF/CostHelper | iFHP 2024, World Population Review 2025 |
| Spinal Fusion (Single Level) | $80,000 - $150,000 | India $10,300 | Thailand $14,000 | Mexico $15,400 | PLOS ONE 2024 / HCUP NIS | iFHP 2024 |
| Heart Valve Replacement | $80,000 - $200,000 | India $8,000 | Turkey $17,200 | Thailand $25,000 | AHA Circulation 2024 | iFHP 2024, OECD Health at a Glance 2025 |
| Bariatric Surgery (Gastric Bypass) | $15,000 - $35,000 | Mexico $4,600 | Turkey $5,500 | India $5,000 | ASMBS, ACS 2024 | iFHP 2024, World Population Review 2025 |
Sources: International Federation of Health Plans (iFHP) 2024 Comparative Price Report, World Population Review 2025, OECD Health at a Glance 2025.
Attachment Point Analysis: Domestic vs International Claims
Typical mid-market specific stop-loss deductibles range from $100,000 to $150,000 for employer groups of 200 to 1,000 employees (Segal, 2025). A domestic total hip replacement at $40,000 to $177,000 may breach a $150,000 threshold depending on regional pricing, facility type, and complication incidence. The same procedure at a JCI-accredited international facility ranges from $12,000 to $25,000 inclusive of facility fees, surgeon fees, and post-operative care. At this pricing level, the claim remains within the employer's funded retention layer and does not trigger stop-loss reimbursement.
The pattern applies across the high-cost procedure categories identified in Sun Life's analysis. Cardiac bypass at $15,000 to $30,000 internationally versus $70,000 to $150,000 domestically. Spinal fusion at $10,300 to $15,400 versus $80,000 to $150,000. Heart valve replacement at $8,000 to $25,000 versus $80,000 to $200,000. In each instance, international published pricing positions the claim below standard specific attachment points. For aggregate stop-loss, reduced individual claim severity directly lowers the probability of total plan claims breaching the aggregate corridor (typically set at 125% of expected claims).
CalPERS provides a partial domestic analogue. When CalPERS introduced reference pricing for joint replacements, 85% of the savings came from domestic hospitals reducing their prices to remain competitive (Robinson and Brown, Health Affairs, 2013), rather than from patients travelling to lower-cost facilities. The mechanism was a reference effect: visible lower-cost alternatives restructured pricing dynamics. CalPERS operated with concentrated purchasing power (approximately 1.5 million covered lives) that a mid-market employer doesn't have. Whether a similar reference effect operates at mid-market employer scale is untested: published international pricing provides a data point for evaluating domestic cost reasonableness, even where the competitive pressure mechanism differs.
Marketplace Infrastructure and Claims Mechanics
For stop-loss underwriting purposes, the marketplace functions as a pricing information layer rather than a managed clinical programme. JCI or equivalent nationally accredited international providers list procedures with published pricing. Plan members browse 1,954 procedures, compare pricing across providers and countries, and book consultations directly with the facility they select. There is no clinical intermediary, no care coordination, and no episode management. The function is comparable to domestic price transparency tools (Healthcare Bluebook, Turquoise Health) applied to international JCI-accredited facilities.
The plan sponsor determines independently whether and how to incentivise member use of international pricing. Common structures documented in the employer-sponsored medical travel literature include cost-sharing waivers at international facilities, travel cost coverage for the member and a companion, and shared savings arrangements (Mercer, 2022). These incentive design decisions are plan-level choices independent of the marketplace infrastructure.
From a claims perspective, international published pricing produces price-certain claims. The cost is established before the member commits to treatment, contrasting with domestic fee-for-service arrangements where final billing is determined post-treatment and subject to provider charge-master variability. This pricing certainty has actuarial implications: the claim amount is a known value rather than a probability distribution, reducing variance in projected plan expenditure.
Carrier Underwriting Implications
Stop-loss carriers evaluate plan risk during underwriting based on claims history, membership demographics, plan design, and cost containment measures in force. A pricing marketplace functions as an information layer rather than a managed clinical program. It does not require actuarial modelling of programmatic outcomes, clinical coordination liability assessment, or episode warranty reserves. The underwriting evaluation is whether the plan has active measures addressing high-cost claimant exposure; published international pricing on the procedure categories driving severity (cardiac, musculoskeletal, bariatric) constitutes such a measure when documented in plan design materials.
Claims completed at international published pricing are price-certain: the dollar amount is fixed before treatment commences. This differentiates them from domestic fee-for-service claims where final costs reflect provider billing practices, network participation status, and post-treatment adjustments. For carriers modelling future exposure, price-certain claims at levels consistently below specific attachment points represent a quantifiable reduction in reimbursement probability. The Phia Group, a cost containment advisory serving stop-loss carriers, notes that carriers provide favourable underwriting consideration when plan sponsors demonstrate proactive cost containment.
Renewal Marketing and Claims Diversion Data
Stop-loss renewal pricing is determined primarily by the plan's claims experience over the preceding 2 to 3 years. Brokers submit loss runs, census data, large claimant reports (claims exceeding 50% of the specific deductible), and cost containment documentation during the marketing process. Claims retained below the specific deductible do not appear in the carrier's reimbursement data. A procedure completed at $25,000 internationally (versus $150,000+ domestically) remains within the employer's funded layer and is absent from the loss run data carriers use to calculate renewal pricing.
The marketplace provides utilisation data for renewal marketing submissions: price lookups by procedure category, consultations booked, procedures completed at international pricing, and estimated savings versus domestic commercial benchmarks. This data supplements standard renewal documentation as evidence of active cost containment addressing the specific high-severity categories (musculoskeletal, cardiovascular, bariatric) that carriers identify as claim drivers.
Medical Stop-Loss Captive Structures
In medical stop-loss captive arrangements (ParetoHealth, Berkley EmCap, Roundstone), member employers pool risk in a member-owned reinsurance vehicle. When aggregate claims fall below actuarial projections, unused premiums return to members as dividends. ParetoHealth represents 2,700 employers with $1.3 billion in managed stop-loss premium. The captive structure creates a direct financial relationship between claims reduction and member economic returns: every dollar not expended on a procedure is available for dividend distribution.
The centers of excellence model is established within captive programmes. Sun Life's SunExcel programme reimburses travel and housing for domestic transplant COE access. Reference-based pricing, direct provider contracting, and network steering are documented captive cost containment strategies. International published pricing extends the savings range: domestic COE programmes document approximately 45% savings per surgical episode (RAND Corporation evaluation of Carrum Health, 2022), while international JCI-accredited facilities publish pricing at 40-80% below US commercial equivalents for the same procedure categories.
Regulatory Framework
No federal or state regulation prohibits stop-loss carriers from crediting claims incurred at international facilities. Stop-loss policies reimburse claims classified as covered charges under the underlying plan document. If the self-funded plan's governing documents define JCI-accredited international facilities as eligible providers, the stop-loss policy credits those claims toward specific and aggregate deductibles under standard contract language. The controlling relationship is between the stop-loss policy and the plan document; the geographic origin of the claim is not a standard exclusion category.
The NAIC Stop Loss Insurance Model Act (92-1) establishes minimum attachment points of $20,000 for specific coverage and 120% of expected claims for aggregate coverage in groups under 51 employees. State minimum deductible requirements vary but none restrict the geographic origin of covered claims. JCI accreditation, administered by an ISQua member organisation evaluating hospitals against over 1,200 measurable elements, provides the international credentialing equivalent to domestic Joint Commission accreditation. Reaccreditation cycles are three years.
Implementation requires two actions from the plan sponsor: (1) plan document amendment to include international facilities as eligible providers, and (2) notification to the stop-loss carrier. International care must be voluntary for plan members per CDC and Department of Labor guidance. Self-funded ERISA plans retain broad authority over benefit design, including determination of covered provider categories and geographic scope of coverage.
Revenue Model and Cost Structure
Providers pay Sylk Health a commission on completed treatment. The commission is drawn from provider revenue and is not added to the member's price. No fee is charged to the plan sponsor, carrier, member, or referring consultant. No subscription, per-member charge, implementation fee, or contract is required. The marketplace can be made available to plan members by including a reference in existing member resources.
Frequently Asked Questions
Stop-loss insurance protects self-funded health plans against claims exceeding predetermined thresholds. Specific stop-loss activates when an individual member's claims exceed the attachment point, typically $100,000 to $150,000 for mid-market employers of 200 to 1,000 employees. Aggregate stop-loss activates when total plan claims exceed a corridor, typically 125% of projected annual spend. According to Segal's 2025 National Medical Stop-Loss Premium Survey, average premiums increased 9.7% year-over-year, with certain carriers implementing increases above 20%.
Medical stop-loss insurance is excess-of-loss coverage purchased by self-funded employers to limit financial exposure on healthcare claims. The US stop-loss market reached $35.4 billion in annual premiums in 2024, with projected growth to $113.5 billion by 2034 at 15.1% compound annual growth (Allied Market Research). When individual or aggregate claims breach the contracted threshold, the stop-loss carrier reimburses the plan sponsor. International procedure options at JCI-accredited facilities can reduce the frequency of claims reaching these thresholds, given published pricing 40-80% below US commercial equivalents.
A stop-loss carrier underwrites excess-of-loss coverage for self-funded health plans. Major carriers include Sun Life, Voya, Tokio Marine HCC, Berkley Accident and Health, Cigna, and Swiss Re Corporate Solutions. Sun Life's 2025 High-Cost Claims Report documents that million-dollar claims per million covered employees rose 61% over four years, with 49% of plans reporting at least one claim exceeding $1 million. Carriers evaluate plan risk based on membership demographics, claims history, plan design characteristics, and cost containment measures in force.
Stop-loss insurance (also termed excess-loss insurance or, in certain contexts, reinsurance) is coverage purchased by self-funded health plan sponsors to limit catastrophic claim exposure. Risk above a defined threshold transfers to the carrier while the plan retains risk below that threshold. Two forms exist: specific (per-member, protecting against individual high-cost claimants) and aggregate (plan-wide, protecting against total claims exceeding actuarial projections). The NAIC Stop Loss Insurance Model Act (92-1) establishes minimum attachment points of $20,000, though typical mid-market deductibles range from $100,000 to $150,000.
The attachment point is the dollar threshold at which stop-loss coverage activates. For specific stop-loss, this is the per-member claims level at which the carrier begins reimbursement. Segal's 2025 survey data indicates typical mid-market specific deductibles of $100,000 to $150,000. For aggregate coverage, the attachment is typically expressed as 125% of expected annual claims. A domestic hip replacement at $50,000 to $177,000 may breach a $150,000 specific attachment point. The same procedure at a JCI-accredited international facility at $12,000 to $25,000 remains within the employer's retention layer.
Aggregate stop-loss coverage activates when total plan claims exceed a predetermined ceiling, typically 125% of expected claims for the plan year. According to Segal's 2025 data, aggregate stop-loss premiums increased 8.8% to 10.5% depending on deductible level. When multiple high-cost procedures occur within a single plan year, they compound toward the aggregate corridor. Each procedure completed at international published pricing (40-80% below US commercial rates) reduces the probability of total claims reaching the aggregate attachment.
Specific stop-loss (individual stop-loss) protects against any single plan member's claims exceeding a set dollar amount. Premiums range from approximately $50 to $230 per employee per month depending on the selected deductible (Segal, 2025). Claims above the specific deductible are reimbursed by the carrier. Sun Life's 2025 data indicates the top 5% of high-cost claimants account for 49.7% of total healthcare spending (AHRQ Medical Expenditure Panel Survey). Published international pricing on procedures driving these high-cost claims positions individual claims below the specific threshold.
No regulatory prohibition exists against stop-loss carriers crediting international claims. Stop-loss policies reimburse claims classified as covered charges under the underlying plan document. If the self-funded plan covers procedures at JCI-accredited international facilities (via plan document amendment), the stop-loss policy credits those claims toward both specific and aggregate deductibles. The plan sponsor must amend the plan document to include international providers and notify the stop-loss carrier. International procedure pricing typically ranges 40-80% below US commercial equivalents, reducing both the frequency and severity of claims breaching attachment points.
Stop-loss carriers evaluate cost containment measures during the underwriting process. Programs that demonstrably reduce high-cost claimant exposure receive favourable consideration in renewal pricing. A pricing marketplace functions as an information layer (comparable to Healthcare Bluebook or Turquoise Health domestically) rather than a managed clinical program. The carrier evaluates whether the plan has measures in place to reduce large-claimant frequency. Published international pricing that enables price-certain claims below standard attachment points constitutes such a measure. The Phia Group notes that carriers provide cost containment credit when employers demonstrate proactive programs reducing large-claimant exposure.
A self-insured (self-funded) employer pays employee healthcare claims directly from operating funds rather than purchasing fully-insured group coverage from a carrier. According to the 2025 KFF Employer Health Benefits Survey, 67% of covered workers are in self-insured plans, rising to 80% at firms with 200 or more employees. Self-insured employers purchase stop-loss to limit catastrophic exposure and contract with third-party administrators (TPAs) for claims processing. These employers have maximum plan design flexibility under ERISA, including the authority to include international providers as covered facilities.
Published Pricing: 1,954 International Procedures
Pricing data from JCI-accredited international facilities, organised by procedure category.
Sylk Health operates an online marketplace listing JCI or equivalent nationally accredited international healthcare providers. Sylk Health is not a healthcare provider, insurance company, health plan, or clinical service. Sylk Health does not provide medical advice, coordinate care, arrange travel, or manage clinical outcomes. All providers listed on the marketplace are independent entities. Patients contract directly with providers. Provider-listed prices are published by the providers themselves and may change without notice. Sylk Health does not set, verify, or guarantee provider pricing. Actual costs depend on individual case complexity, provider selection, and treatment requirements. Content on this page is for informational purposes only and does not constitute medical, legal, actuarial, or fiduciary advice. Plan administrators, carriers, and healthshare ministries should consult their own qualified advisors before making decisions based on information presented here. Sylk Health has no affiliation with any third-party organisation referenced on this page unless explicitly stated.